secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053532
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q2 net loss $31.2M; cash $300.3M; RSV data readouts expected in 2H 2024
------------------------------------------------------------------------------

- Fiscal Q2 2024 revenue $17.1M (AbbVie HCV royalty); net loss $31.2M ($1.47 loss/share) vs $37.7M loss a year ago.
- Cash, equivalents, and marketable securities total $300.3M; expected runway through Q3 FY2027.
- Zelicapavir Phase 2 pediatric RSV data expected 2H 2024; EDP-323 challenge study data expected Q3 2024.
- KIT inhibitor development candidate for CSU targeted Q4 2024; second immunology program planned in 2024.
- Expense guidance updated: R&D $125M-$145M, G&A $50M-$60M due to immunology/RSV efforts and Pfizer patent lawsuit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017024053532/0000950170-24-053532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017024053532/enta-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer